Sana Biotechnology (NASDAQ:SANA) Trading Up 5.3%

Sana Biotechnology, Inc. (NASDAQ:SANA) shares were up 5.3% during trading on Wednesday . The stock traded as high as $8.60 and last traded at $8.52. Approximately 782,879 shares were traded during trading, a decline of 74% from the average daily volume of 3,042,173 shares. The stock had previously closed at $8.09.

Analysts Set New Price Targets

Several analysts have recently commented on SANA shares. JMP Securities increased their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “market outperform” rating in a report on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Sana Biotechnology in a research note on Friday, March 1st.

Sana Biotechnology Stock Performance

The stock has a 50 day moving average of $9.04 and a 200-day moving average of $6.03. The company has a market cap of $1.89 billion, a PE ratio of -5.84 and a beta of 1.61.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. During the same period in the previous year, the business posted ($0.40) EPS. Equities research analysts forecast that Sana Biotechnology, Inc. will post -1.02 EPS for the current year.

Insider Buying and Selling at Sana Biotechnology

In related news, Director Robert Nelsen acquired 1,818,181 shares of Sana Biotechnology stock in a transaction on Thursday, February 8th. The stock was acquired at an average price of $5.50 per share, for a total transaction of $9,999,995.50. Following the purchase, the director now owns 12,446,022 shares of the company’s stock, valued at approximately $68,453,121. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 34.90% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Sana Biotechnology by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,167,585 shares of the company’s stock valued at $35,479,000 after acquiring an additional 107,167 shares during the period. PFM Health Sciences LP grew its position in shares of Sana Biotechnology by 51.4% during the 4th quarter. PFM Health Sciences LP now owns 1,883,337 shares of the company’s stock valued at $7,684,000 after acquiring an additional 639,198 shares during the period. State of Michigan Retirement System acquired a new stake in shares of Sana Biotechnology during the 3rd quarter valued at about $2,663,000. GSA Capital Partners LLP acquired a new stake in Sana Biotechnology in the 3rd quarter worth about $2,091,000. Finally, Deutsche Bank AG boosted its holdings in Sana Biotechnology by 1.8% in the 3rd quarter. Deutsche Bank AG now owns 478,482 shares of the company’s stock worth $1,852,000 after buying an additional 8,408 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.